Catalyst Wire Dossier Catalyst Wire Dossier

Imlygic

Talimogene laherparepvec · Amgen
Drug timelines are a Plus or Pro feature.

14 regulatory and trial events tracked for Imlygic, covering 2015-12-17 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers [Phase 2]

See pricing